RICHMOND, BC, July 3, 2012 /CNW/ - MacDonald, Dettwiler and Associates
Ltd. (TSX: MDA), a provider of essential information solutions, has received
additional funding from the Centre for Surgical Invention and
Innovation (CSii) at McMaster University for the next phase of
development of the advanced technology solution for use in early
detection and treatment of breast cancer. The total contract is now
valued at CA$7.7 million.

This next phase will include enhancing the capability of the original
solution, and integrating it into the complete platform in preparation
for clinical trials.

As announced in August 2011, MDA and CSii are collaborating on the
development of a platform of Image Guided Autonomous Robotic products,
the first of which is designed to perform image-guided breast
biopsies. The solution will provide increased access, precision and
dexterity resulting in more accurate and less invasive procedures.

About MDA

MDA provides advanced information solutions that capture and process
vast amounts of data, produce essential information, and improve the
decision making and operational performance of business and government
organizations worldwide.

This release contains forward-looking statements and information, which
reflect the current view of MacDonald, Dettwiler and Associates Ltd.
("MDA") with respect to future events and financial performance. The
forward-looking statements in this regard include statements regarding
the award of a contract. Any such forward-looking statements are based
on MDA's current expectations, estimates, projections and assumptions
in light of its experience and its perception of historical trends.
The factors and assumptions underlying the forward-looking statements
in this release include contracts not being terminated. Any such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially from
current expectations. MDA cautions readers that should certain risks or
uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary significantly from those expected.
The risks that could cause actual results to differ from current
expectations include failure of third parties and subcontractors;
failure of systems to meet performance requirements and failure to
anticipate changes in technology, technical standards and offerings or
comply with the requisite standards.

For additional information with respect to certain of these risks or
factors, plus additional risks or factors, reference should be made to
MDA's continuous disclosure materials filed from time to time with
Canadian securities regulatory authorities, which are available online
at www.sedar.com or on MDA's website at www.mdacorporation.com.

The Toronto Stock Exchange has neither approved nor disapproved the form
or content of this release.